Format

Send to

Choose Destination
Am J Manag Care. 2015 Dec;21(16 Suppl):s331-40.

The economic implications of biosimilars.

Author information

1
surya.singh@cvshealth.com.

Abstract

Between 2013 and 2014, spending on specialty drugs, including biologics, increased 32.4%, while spending on small-molecule drugs increased just 6.8%. By 2016, 8 of the 10 top-selling drugs are expected to be biologics. While many biologics will be going off patent, there will likely be multiple prospective manufacturers of biosimilars, and a growing emphasis on regulatory guidelines to ensure their efficacy and safety, in the very near future. A strong factor and assumption surrounding biosimilar development and use is the potential for healthcare cost savings; the introduction of biosimilars is expected to reduce drug costs, although to a lesser degree than seen with small-molecule generic drugs. Managed care clinicians and providers must carefully consider the economic implications and potential cost-effectiveness of uptake of biosimilars for therapy in clinical practice.

PMID:
26788809
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Managed Care & Healthcare Communications, LLC
Loading ...
Support Center